Dulaglutide 1.5 mg reduced SBP and pulse pressure in people with T2D across the placebo-controlled trials in the AWARD program (Cardiovascular Diabetology)
Diabetes News
Tag: Dulaglutide
Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes
Treatment with dulaglutide at a once-weekly dose of 0.75 mg or 1.5 mg was superior to placebo in improving glycemic control through 26 weeks among youths with type 2 diabetes who were being treated with or without metformin or basal insulin, without an effect on BMI (NEJM)
Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes
Treatment with dulaglutide at a once-weekly dose of 0.75 mg or 1.5 mg was superior to placebo in improving glycemic control through 26 weeks among youths with type 2 diabetes who were being treated with or without metformin or basal insulin, without an effect on BMI (NEJM)
Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
The tolerability profiles of dulaglutide 3.0 mg and 4.5 mg were consistent with that of the 1.5-mg dose. Patients experiencing GI events were most likely to do so within 2 weeks of treatment initiation, and few patients experienced a new GI event after escalating to the 3.0-mg or 4.5-mg dose. Severe events were infrequent, and when they did occur, no relationship with dose at time of event was observed (Diabetes Therapy)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Dulaglutide could be considered for the management of glycaemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors (Lancet)
Evaluation of the Long‐Term Cost‐Effectiveness of Once‐Weekly semaglutide versus dulaglutide for the treatment of type 2 diabetes mellitus in the UK
Compared with treatment with dulaglutide, once‐weekly semaglutide represents a cost‐effective option for treating people with T2DM not achieving glycaemic control on metformin in the UK, projected to both improve clinical outcomes and reduce costs (Diabetes, Obesity and Metabolism)
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)
In patients with type 2 diabetes and moderate-to-severe chronic kidney disease, once-weekly dulaglutide produced glycaemic control similar to that achieved with insulin glargine, with reduced decline in eGFR. Dulaglutide seems to be safe to use to achieve glycaemic control in patients with moderate-to-severe chronic kidney disease (The Lancet Diabetes & Endocrinology)
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10)
Dulaglutide as add-on treatment to SGLT2 inhibitors (with or without metformin) resulted in significant and clinically relevant improvements in glycaemic control, with acceptable tolerability that is consistent with the established safety profile of dulaglutide (The Lancet Diabetes & Endocrinology)
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
At low and high doses, semaglutide was superior to dulaglutide in improving glycaemic control and reducing bodyweight, enabling a significantly greater number of patients with type 2 diabetes to achieve clinically meaningful glycaemic targets and weight loss, with a similar safety profile (The Lancet Diabetes & Endocrinology)
Once Weekly Dulaglutide 1.5 mg Restores Insulin Secretion in Response to Intravenous Glucose Infusion
In subjects with T2DM, a single dulaglutide 1.5-mg dose restored the first-phase insulin secretion in response to an IV glucose bolus, increased the second-phase insulin response and enhanced β-cell function (Diabetes, Obesity and Metabolism)
Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis
Although weight reduction is seen with all GLP-1RA’s, only the once weekly agents, exenatide LAR and dulaglutide, demonstrate significant HbA1c reductions when compared to basal insulins (Diabetes, Obesity and Metabolism)
Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events
These results suggest that dulaglutide does not increase the risk of major CV events in T2D patients. The ongoing CV outcomes study, Researching CV Events with a Weekly Incretin in Diabetes (REWIND), will further assess CV safety of dulaglutide (Cardiovascular Diabetology)
Achieving the Composite Endpoint of HbA1c<7.0%, No Weight Gain, and No Hypoglycaemia in the Once Weekly Dulaglutide AWARD Program
Dulaglutide is an effective treatment option, resulting in a similar or greater proportion of patients who reached the HbA1c target of <7.0% (53 mmol/mol), without weight gain or hypoglycaemia compared to active comparators (Diabetes, Obesity and Metabolism)
Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4)
Dulaglutide in combination with lispro resulted in a significantly greater improvement in glycaemic control than did glargine and represents a new treatment option for patients unable to achieve glycaemic targets with conventional insulin treatment (Lancet)
Glycosmedia is also available as an App: